Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), a European leader in Forensic DNA
and Toxicology testing in France, Germany and Belgium, announces
that it has signed an agreement to acquire the Forensics and
Security division of LGC (“LGC Forensics”), the largest player in
the UK forensics market, a European pioneer in this field and a
significant forensic DNA testing provider in Germany, from LGC
Group. The transaction is expected to close in the coming weeks,
upon fulfillment of customary closing conditions.
LGC Forensics provides the most comprehensive range of forensic
science services including casework, DNA testing, digital
forensics, drugs and toxicology and firearms. The company has over
120 accredited methods, significantly more than any of their
competitors. LGC Forensics completes over 34,000 casework
investigations per annum. LGC Forensics is one of the most trusted
forensic services providers in the world, benefitting from strong
customer relationships with major police forces in the UK, Germany
and the Netherlands. The company employs over 650 staff in eight
locations, seven in the UK and one in Germany, and generates annual
revenues in excess of EUR 45m.
The acquisition of LGC Forensics is an opportunity for Eurofins
Forensics to reshape the European forensic market, thanks to the
combination of Eurofins and LGC Forensics’ capabilities and
industry-leading delivery performance. Eurofins’ offering in the
forensic market is now unique, with its scientific consulting,
expert witness services, strengthened DNA testing (more than
500,000 samples processed annually) and toxicology testing. This
market has significant growth opportunities stemming from
regulator’s increased focus on quality standards and accreditation,
as well as growing outsourcing trends. Additionally, LGC Forensics’
digital forensic services will provide Eurofins with new,
state-of-the-art, skills and technologies including: computer and
mobile phone forensic services, cell site analysis, imagery and
audio analysis. Digital forensics is a clear development path for
the future of the forensics market, which is characterized by an
increasing prevalence of cyber-crimes.
Comment from Dr. Gilles Martin, Eurofins’ CEO: “We
are pleased to welcome LGC Forensics, a highly renowned laboratory
group, to Eurofins’ family of businesses. In addition to the large
volume of DNA testing it carries out, LGC Forensics adds another
spectrum of new advanced services that Eurofins can now offer to
its clients. In return, LGC Forensics will gain access to the
Group’s entire portfolio of competencies, logistics and clients,
which should help reinforce their leadership in the UK and German
forensics markets and expand their offering to other European
countries. This transaction is another demonstration of Eurofins’
commitment to acquire advanced technologies to expand its
state-of-the-art portfolio of analytical services.”
Dr. Mark Pearse, Managing Director, LGC, Forensic and
Security Division: “I am delighted that we will soon be part of
Eurofins. This news follows the division’s recent commercial
successes, both in the UK and abroad, and is testament to the
team’s commitment to develop innovative operational models, working
in close partnership with the UK forces. As we begin to see greater
stability in the funding and delivery of forensics in the UK,
Eurofins will continue to provide leadership long in to the future,
building on the expertise of our world-renowned employees.”
Tim Robinson, CEO LGC, said: “We are proud to have played
a crucial role in the UK forensics landscape in the last two
decades. During that time, LGC has invested significantly in
improving the efficiency and effectiveness of delivering forensic
evidence, with a very strong focus on quality and
innovation. I am confident that the business is set for a
successful and exciting future under the global reach and
scientific expertise of Eurofins.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 375 laboratories across 41 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
LGC
LGC is an international leader in the extended life sciences
sector, including human healthcare, agri-food & the
environment. LGC provides a comprehensive range of reference
materials, proficiency testing schemes, genomics reagents and
instrumentation, as well as research and measurement services. Its
scientific tools and solutions enable organisations to advance
research, develop new products and form an essential part of their
quality and compliance procedures.
LGC’s 2,000 employees include internationally-recognised
scientists who are experts in their field. Headquartered in London,
it operates out of 19 countries worldwide and is extensively
accredited to quality standards such as GMP, GLP, ISO 13485, ISO
17034, ISO 17043, ISO/IEC 17025 and ISO 9001.
LGC has been home to the UK Government Chemist for more than 100
years and is the UK National Measurement Laboratory and Designated
Institute for chemical and bio measurement. LGC has been
privately-owned since 1996 and has diversified through internal
investment and acquisition to be an international leader in its
chosen niche markets. LGC is now owned by funds affiliated with
KKR.
For more information, please visit www.lgcgroup.com
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171011006395/en/
Investor RelationsEurofins Scientific+32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From May 2023 to May 2024